Expert review of anticancer therapy
-
Expert Rev Anticancer Ther · Jan 2016
Comparative StudyNivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
Lung cancer still remains associated with a high mortality rate and more efficacious therapies are needed in order to improve the disease outcome. Nivolumab is a monoclonal antibody which blocks the programmed death-1 receptor which is currently evaluated in phase III clinical trials in advanced lung cancer. ⋯ Further clinical data are needed in order to better position this therapy among the existing methods. The promising results support the use of this therapy as a stand-alone approach.